Tufts University

On Target Therapeutics LLC

I2 Technologies Us, Inc.

I2 Technologies, Inc.

Krishna Kumar

Alan S Kopin

Charles M Cohen

Jamie Raudensky Doyle

Xuechao Xing

Pedram Hamrah

Jonathan M Cherneff

Benjamin N Harwood

Venkata S Raman

Vittorio Montanari

Alfio Fichera

Zihni Bilgicer

David L Kaplan

John Fors

Junqi Wu

Morgan Hawker

Julia Fountain

Martin Beinborn

The present disclosure relates to compositions, methods of making, and methods of using a modified silk-based composition having a selectively tunable hydrophobicity. The provided compositions include silk fibroin having a haloalkyl substituent. The haloalkyl substituent is coupled to an amino acid of the silk fibroin though a linking agent.

Hydrophobic silk fibroin compositions and methods of making the same

The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

Soluble lipidated ligand agents for treating eye inflammation

The present disclosure relates to, among other things, compositions and methods for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain. One aspect of the present disclosure relates to a composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof.

Methods for treating symptoms of dry eye disease

The present disclosure relates to, among other things, compounds and methods for treating neuropathic pain, ocular pain, ocular inflammation, and/or dry eye and methods of detecting mutations in specific G-protein coupled receptors, such as missense mutations, and determining the extent to which these mutations alter the pharmacological response of the G-protein coupled receptor.

Bovine adrenal medulla peptide 8-22 compounds and methods of use thereof for treating pain

Methods and systems for designing and/or characterizing soluble lipidated ligand agents

Methods of lowering blink reflex for the treatment of dry eye disease

Compounds and methods for treating pain

Aspects of the present invention relate to compounds for preparing fluorocarbon compounds, methods for preparing fluorocarbon compounds, and methods for purifying a mixture of compounds. One aspect of the present invention relates to a trivalent iodonium fluorocarbon. The trivalent iodonium fluorocarbon compound of the invention is useful for attaching a fluorocarbon group to a compound that has a nucleophilic functional group. Another aspect of the present invention relates to a method of preparing a trivalent iodonium fluorocarbon. Another aspect of the present invention relates to a method of preparing a fluorocarbon by treating a compound bearing a nucleophilic functional group with a trivalent iodonium fluorocarbon compound. Another aspect of the present invention relates to a method or purifying a mixture comprising a first and a second compound by treating the mixture with a trivalent iodonium fluorocarbon to attach a fluorocarbon group to the second compound leaving the first compound unchanged, and purifying the mixture by fluorous-phase purification.

Fluorous capping reagents and methods for peptide purification

One aspect of the invention relates to hexafluoroleucine and congeners thereof, and methods of making the compounds. Another aspect of the invention relates to the synthesis of protein cores comprising hexafluoroleucine and congeners thereof. Certain peptides comprising hexafluoroleucine and congeners thereof have been characterized using comparative biophysical studies. In general, the fluorinated peptides show higher thermal stability and enhanced resistance to chemical denaturation. Further, mixed hydrocarbon-fluorocarbon cores self-sort into homogeneous bundles, suggesting new avenues for the design and manipulation of protein-protein interfaces.

Non-racemic trifluoroleucine, and methods of making and using

A product development scheduler uses a distributed, constraint based system for modeling allocation of resources. All resources for all active development projects are provided at a central location, so that resources are not allocated twice across different projects. Real time availability of resources allows accurate modeling, and changes in resource status are reflected by the scheduler. Availability of materials are tracked through the supply chain to ensure true availability for planning purposes.

System for scheduling product planning

One aspect of the invention relates to hexafluoroleucine and congeners thereof, and methods of making the compounds. Another aspect of the nvention relates to the synthesis of protein cores comprising hexafluoroleucine and congeners thereof. Certain peptides comprising hexafluorleucine and congeners thereof have been characterized using comparative biophysical studies. In general, the fluorinated peptides show higher thermal stability and enhanced resistance to chemical denaturation. Further, mixed hydrocarbonfluorocarbon cores self-sort into homogeneous bundles, suggesting new avenues for the design and manipulation of protein-protein interfaces.

Non-racemic hexafluoroleucine, and methods of making and using it

A computer-implemented system (,) for product development planning. The system (,) models a business enterprise in terms of its proposed products and the tasks and resources used to develop them. A optimizing engine comprised of a genetic algorithm (,) and a constraint engine (,) operates on the model to construct candidate product portfolios and schedules. Each schedule is evaluated and used to generate an &ldquo;improved&rdquo; candidate portfolio in accordance with genetic processing. This process continues to improve the product prioritization and pipeline schedule as measured in terms of an objective criterion such as profit maximization.

Growing community of inventors

Cambridge, MA, United States of America

Krishna Kumar